June 3, 2011 -- Maquet Cardiovascular announced that the U.S. Food and Drug Administration (FDA) has granted the company 510(k) clearance to market its CardioRoot aortic graft in the United States. A one-piece design, aortic root graft, CardioRoot will be used by vascular and cardiovascular surgeons to surgically repair or replace diseased and damaged aortae. CardioRoot is now commercially available in the United States. CardioRoot’s design mimics the anatomy of the patient’s native aortic root, including the clinically important natural sinuses of valsalva, which supply blood to the heart’s own arteries. CardioRoot’s anatomically correct shape allows easy sewing of valve remnants or a prosthetic valve within the tube, thereby avoiding potential bleeding while shortening surgical procedure time. “The CardioRoot graft is an important option for aortic root repair. The graft wall is supple, allowing better approximation with tissue. The unique properties of the graft material provide ease of suturing and superb predictability of the final geometry,” said Marc W. Gerdisch, M.D., chief of cardiothoracic surgery at Franciscan St. Francis Heart Center in Indianapolis, and a clinical assistant professor of cardiothoracic surgery at Loyola University Medical Center. Dr. Gerdisch is the first cardiothoracic surgeon in the United States to use CardioRoot on a critically ill patient. “The improved hemostasis is an added advantage of CardioRoot for complex aortic root reconstructions, substantially contributing to a dry surgical field at the end of the surgery." For more information: www.maquet.com
Technology | June 03, 2011
Maquet Cardiovascular Receives 510(K) Clearance To Market Cardioroot Aortic Graft In U.S.
News | Clinical Decision Support| October 16, 2017
The American College of Cardiology (ACC), along with several partnering societies, recently released appropriate use...
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
News | Heart Valve Technology| October 02, 2017
Medtronic plc recently announced a new post-market clinical study to evaluate its CoreValve Evolut Pro valve in...
News | Robotic Systems| September 22, 2017
The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and...
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
News | Cardiovascular Surgery| September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Feature | September 11, 2017
September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has sele
News | Cardiovascular Surgery| September 08, 2017
September 8, 2017 — ClearFlow Inc.